In the BioHarmony Drug Report Database
Besivance (besifloxacin) is a small molecule pharmaceutical. Besifloxacin was first approved as Besivance on 2009-05-28. It is used to treat bacterial conjunctivitis, bacterial infections, and protozoan infections in the USA. Besivance’s patents are valid until 2031-01-09 (FDA).
Image (chem structure or protein)